Affymetrix — Merger or Acquisition (May 2005)
56 slides from Affymetrix's merger presentation, May 31, 2005
Slide 1: Forward Looking Statements
Forward Looking Statements All statements in this presentation that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategie
Slide 2: Important Information For ParAllele Investors And Shareholders
Important Information For ParAllele Investors And Shareholders Affymetrix will file a registration statement on Form S-4 containing a prospectus with the SEC in connection with its proposed acquisition of ParAllele. Affymetrix urges ParAlleles investors and shareholders to read these documents when
Slide 3: Agenda
Agenda o Affymetrix: The Company o The Power of Photolithography o Products o Customers, Markets, & Business Models o Working Together o Human Resources o Next Steps and Q&A
Slide 4: Milestones in Affymetrix Evolution
Milestones in Affymetrix Evolution
Slide 5: Milestones in Affymetrix Evolution
lestones in Affymetrix Evolution Toor T war Tvo00 T toon T toon T rose T war 1 vo0e Twos T 2op0 T avon 1 2002 T 2000 1 2008 17 2008 sereicrn, oa KO: 7] or ee enor sa “se
Slide 6: Global Infrastructure
Global Infrastructure o Headquartered in Santa Clara, CA o NASDAQ: AFFX (IPO in 1996) o Employees ~ 900
Slide 7: Affymetrix & ParAllele: Shared Mission
Affymetrix & ParAllele: Shared Mission! Affymetrix Corporate Mission To be the leading source of molecular technologies to understand and improve life. Mission Statement ParAllele ParAllele will be the leading supplier of innovative solutions for understanding how genetic variation impacts human hea
Slide 8: Historic Financial Performance
Historic Financial Performance o Installed base > 1200 instruments worldwide o Over 500,000 chips shipped in 2004 o >300 patents issued o 3000 peer reviewed papers
Slide 9: Historic Financial Performance
Historic Financial Performance The Wey Ahoad™ 0 $125 (ears reve lmmctrcoe 059 Oo) Lees = 75 20 =) 025 = a rn se = a er) > om $0.25 ex om $079 00) = $0125
Slide 10: Agenda
Agenda o Affymetrix: The Company o The Power of Photolithography o Products o Customers, Markets, & Business Models o Working Together o Human Resources o Next Steps and Q&A
Slide 11: Affymetrix: The Company
Affymetrix: The Company The Power of Photolithography Products Customers, Markets, & Business Models Working Together Human Resources Next Steps and Q&A
Slide 12: Arrays, Chips, and Features
APEYUETAYS KYO. Chips/wafer 41.28cm 1.28cm Up to ~1,300,000 features /chip rs, Chips, and Features Millions of identical probes /feature
Slide 13: Moore's Law - Array Information Capacity
Moore's Law - Array Information Capacity
Slide 14: GMP Compliant and ISO/QSR Certified GeneChip Probe Array Manufacturing
GMP Compliant and ISO/QSR Certified GeneChip® Probe Array Manufacturing
Slide 15: Agenda
Agenda o Affymetrix: The Company o The Power of Photolithography o Products o Customers, Markets, & Business Models o Working Together o Human Resources o Next Steps and Q&A
Slide 16: Affymetrix: The Company
Affymetrix: The Company The Power of Photolithography Products Customers, Markets, & Business Models Working Together Human Resources Next Steps and Q&A
Slide 17: Expression Variability / Sequence Variability
> Expression Variability mRNA Analysis) rer iss AIA All iB sequence Variability Resequencing >: Basic & Clinical R&D + Academic Pharma R&D Molecular Dx + Emerging Markets + Testing & Identification
Slide 18: From Sequence to Function
KG From Sequence to Function The Wry Ahead fig 1 fun users eig dried yt CODE ple pha. The nated thos ae ing tery ert pes of ‘Setond canes ston gesone ual fee iano ‘Science, Yol 208, sue 5698, 636-640 , 22 October 2004
Slide 19: Affymetrix Product Lines
Affymetrix Product Lines The Way Ahead.” AS GeneChip® Expression Array Products EUKARYA Bam Beams ‘Sequence Databases xia OascineExprnson Ara
Slide 20: Customer Workflow: Understanding Genetics of Disease
AFFYMET! Affymetrix Product Lines The Way Ahead.” KC. Customer Workflow: Understanding Genetics of Disease Description Product Linkage & association EEE Targeted Reduce to candidate + MIP genotyping SNPsiregions/genes Perlegen 10K, 100K, 500K+ MIP. Scan whole genome Sequence | Identiy candidate cust
Slide 21: GCS3000Dx Launch
-erstanaing GCS3000Dx Launch World's First Diagnostic Pharmacogenomic Microarray System for European Union & North America ‘GCS 3000Dx System AmpliChip CYP450 Test
Slide 22: Affymetrix Product Lines
Affymetrix Product Lines Fluidics Station GCS 2000Dx HT Scanner
Slide 23: Formed Perlegen to Drive New Applications
Formed Perlegen to Drive New Applications
Slide 24: Formed Perlegen to Drive New Applications
ned Perlegen to Drive New Applications JAFFYMETRIX, — | Supply wafers & chips LD pp ly, P: , Dl ———y PERLE! Generate Information Inforrlation for chipidesign _ < drug development eS Association studies [ma] & biological research for
Slide 25: Agenda
Agenda o Affymetrix: The Company o The Power of Photolithography o Products o Customers, Markets, Business Models o Working Together o Human Resources o Next Steps and Q&A
Slide 26: Agenda
The Wry Ahead Agenda Affymetrix: The Company The Power of Photolithography Products Customers, Markets, Business Models Working Together Human Resources Next Steps and Q&A
Slide 27: Molecular Diagnostics, Emerging Markets
Molecular Diagnostics, Emerging Markets Ooo € Wate | ParAllele| >
Slide 28: GeneChip Technology in Academic Centers
The Wry Ahead SELECTED CENTERS + Sanger Institute + Harvard University ‘Dana Farber Ca Insite = MIKINCL + Stanford University + Columbia University Canadian Gene! Diseases Network sity of Colorado =H ing Hart Cystic Fi Foundation Duke University RIKEN GeneChip® Technology in Academic Centers
Slide 29: GeneChip Technology in Drug Development
AFFYMETRIX Discovery) Validation and) Pre-Ciinicalland) Optimization) Glinicall trials; + ~200 publications referencing GeneChip® technology in drug development + Schering-Plough Abbott Sankyo a6 . ; Roc! + >650 clinical trials ongoing or Weeki 8 completed for 2004-05 involving 5 GeneChip® technolog
Slide 30: PbA: Powered by Affymetrix Partnership Model
PbA: Powered by Affymetrix Partnership Model o 'Intel Inside' o Non-exclusive relationships o PbA partner develops & commercializes products Roche o Combines the power of two industry gold standards: PCR & GeneChip® technology for human diagnostic products Veridex LLC o Develops & commercializes bro
Slide 31: Emerging Markets: Applied Testing Applications
Emerging Markets: Applied Testing Applications
Slide 32: Development of Standards & Controls
Development of Standards & Controls Leadership in industry, academic, and national agency consortia
Slide 33: Affymetrix Public Policy Priorities
Affymetrix Public Policy Priorities o Genetic privacy and non-discrimination o Government funding of translational research o IP: no patents on naturally occurring genes o Formalized research exemption
Slide 34: Affymetrix Public Policy Priorities
Affymetrix Public Policy Priorities Genetic privacy and non-discrimination Government funding of translational research IP: no patents on naturally occurring genes Formalized research exemption
Slide 35: A New Paradigm in NIH Funding
A New Paradigm in NIH Funding A New Paradigm in NIH Funding o Harmonization of Clinical Research Regulatory Processes o Integration of Clinical Research Networks o Enhancing Clinical Research Workforce Training o National Electronic Clinical Trials & Research System (NECTAR) o Regional Translational
Slide 36: Growing International Biobanking Activities
Growing International Biobanking Activities US efforts include: o Mayo Clinic o Marshfield Personalized Medicine o Framingham Heart Study o National Childrens Study o Nurses' Health Study o American Cancer Society CPS-II o CDC NHANES III
Slide 37: Affymetrix & Translational Medicine
Affymetrix & Translational Medicine Affymetrix technology becomes the standard in genetic profiling within biobanks
Slide 38: Agenda
Agenda o Affymetrix: The Company o The Power of Photolithography o Products Customers & Markets o Working Together Human Resources o Next Steps and Q&A
Slide 39: Affymetrix: The Company
Affymetrix: The Company The Power of Photolithography Products Customers & Markets Working Together Human Resources Next Steps and Q&A
Slide 40: Why We Think This Makes Sense
Why We Think This Makes Sense Affymetrix brings: o Industry-leading DNA business (largest and fastest-growing) o Universal market presence, reach and brand ParAllele brings: o Innovative, leading genetics assays o Capabilities for both products and services o Talented, versatile people Together, we
Slide 41: Customer Workflow: Understanding Genetics of Disease
Customer Workflow: Understanding Genetics of Disease
Slide 42: Our Business Vision
Our Business Vision o Fundamental vision: More information enables customers to make better decisions - Customers used to 100 SNPs or 700 bases - More information too expensive or hard to analyze - We need to deliver more complete information effectively and affordably o Enable whole genome DNA anal
Slide 43: Evolution of Our Relationship
Evolution of Our Relationship (Our Perspective) Get to know each other 2003 1st agmt (Joint Dev) Friendly, but uncommitted Date 2004 2nd agmt (Joint Dev & Cmml) Cautiously optimistic, but still long-term uncommitted Are we right for each other? 2005 Discussing wide range of possibilities Enthusiasti
Slide 44: What to Expect From Us
What to Expect From Us We WILL o Drive business growth faster than either of us could have alone o Seek to establish this assay as the market standard for genotyping (and other applications) o Create opportunities for you to lead as part of the market leader We WON'T o Know all the answers -- we nee
Slide 45: Key Near-Term Priorities
Key Near-Term Priorities o Launch 1st generation system (complete) o Develop clear joint plan for next generation system - Marketing drives requirements - Product development drives workplan o Invest in the business - Technology development - New application development - Standard panels o Prioritiz
Slide 46: Agenda
Agenda o Affymetrix: The Company o The Power of Photolithography o Products o Customers & Markets o Working Together o Human Resources o Next Steps and Q&A
Slide 47: Affymetrix: The Company
Affymetrix: The Company The Power of Photolithography Products Customers & Markets Working Together Human Resources Next Steps and Q&A
Slide 48: Affymetrix Human Resources
AFEYMETRIX, The Way Ahead” Affymetrix Human Resources
Slide 49: HR Philosophy
AFEYMETRI HR Philosophy = Market Competitive Compensation and Benefits = Believe in investing in training and development = HR partners are experienced and accessible
Slide 50: Compensation Philosophy
WOE The Wry Ahead = To ensure that employees’ total compensation is aligned with their performance and value to the organization as well as the external market — We Pay for Performance — We pay according to competitive market trends — We focus on Total Compensation = Base Pay (experience & skills, r
Slide 51: Quick Benefits Comparison
Quick Benefits Comparison PARALLELE BENEFITS AFFYMETRIX BENEFITS Eligibility Must work 30 hours Eligibility Must work 20 hours BENEFIT EMPLOYEE COST DEPENDENT COST COMMENTS BENEFIT EMPLOYEE COST DEPENDENT COST COMMENTS Medical Medical Blue Cross PPO 0% 50% Blue Shield PPO (California and Non-Califor
Slide 52: Agenda
Agenda || Affymetrix: The Company || The Power of Photolithography || Products || Customers, Markets, & Business Models || Working Together || Human Resources || Next Steps and Q&A
Slide 53: Next Steps
Next Steps || Day to Day: "business as usual" to deliver on our mutual goals & objectives || Integration team has been defined, with representation from both Affymetrix and ParAllele || Be patient with each other! || The teamwork continues!
Slide 54: Affymetrix & ParAllele: Driving the Genetic Revolution
Affymetrix & ParAllele: Driving the Genetic Revolution
Slide 55: AFFYMETRIX, d
AFFYMETRIX, d AG2 wero ma —_ Basic Research Personalized medicine
Slide 56: Questions?
ae, AFEYMETRIX, The Way Ahead” Questions?